ABOUT THIS EVENT

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, rings the Nasdaq Closing Bell remotely from across the country.

• C4T is poised to become the third targeted protein degradation (TPD) company to complete an IPO this year, showing substantial progress for companies advancing therapies in this rapidly emerging sector of the biotech market
• There has been significant investment in TPD companies ($3.5B invested to date according to ReportLinker Market Report) including C4T, representing substantial funding to support further development in this exciting therapeutic area
• TPDs represent a novel therapeutic approach, designed to destroy disease causing proteins rather than follow more traditional protein targeting approaches that work to interrupt enzymatic processes
• TPD’s unique mechanism of action may overcome the limitations of traditional protein targeted approaches and enable the targeting of previously “undruggable” targets, positioning the class to address a large and diverse set of indications
• C4T is differentiated in the TPD space through its TORPEDO™ platform, which enables C4T to synthesize small molecule protein degraders in a variety of disease areas, with lead assets focused in oncology indications such as multiple myeloma

In celebration of its IPO, Marc A. Cohen, Co-Founder, Executive Chairman & CEO, rings the Closing Bell alongside the Company’s team in a virtual bell ringing ceremony.